Researchers looking for dietary interventions for diseases have found promoting gut microbiota to hold great promise. Unsurprisingly, clinicians harp on certain foods or diet patterns for patients with inflammatory conditions. As a result, strategies consisting of promoting intestinal-friendly gut bacterial are becoming more clinical significance. Particularly, for patients with intestinal diseases, the strategy is gaining clinical currency. A team of researchers from University Medical Center Groningen, Netherlands has concluded that certain plant-based foods and Mediterranean diet aids in setting a healthy gut microbiome in individuals. A healthy gut microbiome engender growth of colon cells by synthesizing essential nutrients for these cells.
The scope of the study was wide. The work comprised analyzing three cohorts of populations who suffer from Crohn’s disease, ulcerative colitis, and irritable bowel syndrome (IBS). The fourth study group comprise general population. The study looked at stool markers in them and delineated 61 distinct food items and 49 correlations with food patterns.
Researchers Reiterate Certain Foods to Promote Gut-Friendly Bacteria
The findings of the result, though, weren’t surprising. Nonetheless they reiterated some of the common health food beliefs. The food items that promote the functions of healthy bacteria caused less intestinal inflammation. They aided the biosynthesis of vitamins and amino acids. The researchers concluded that plant-based diets rich in bread, legumes, nuts, vegetables, fruit, are cereals were beneficial to gut microbiota. On the other hand, those meat, fast foods, and food containing refined sugar had the contrary effects on the gut microbes. They also recommended people to take fish, lean meat, red wine, and poultry in moderate amounts, as they may hamper a healthy gut ecosystem.
Interestingly, the effects of animal-derived and plant-derived protein were inversely proportional on the gut microbiota, researchers added.
Intestinal diseases have considerable health burden, both in terms of deaths and healthcare costs, notably in European countries. These results will likely advance the treatment regimens of these diseases.